267 related articles for article (PubMed ID: 8683316)
1. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET.
Gupta NC; Maloof J; Gunel E
J Nucl Med; 1996 Jun; 37(6):943-8. PubMed ID: 8683316
[TBL] [Abstract][Full Text] [Related]
2. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan.
Dewan NA; Shehan CJ; Reeb SD; Gobar LS; Scott WJ; Ryschon K
Chest; 1997 Aug; 112(2):416-22. PubMed ID: 9266877
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
[TBL] [Abstract][Full Text] [Related]
4. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Gupta NC; Frank AR; Dewan NA; Redepenning LS; Rothberg ML; Mailliard JA; Phalen JJ; Sunderland JJ; Frick MP
Radiology; 1992 Aug; 184(2):441-4. PubMed ID: 1620844
[TBL] [Abstract][Full Text] [Related]
5. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of radiographically indeterminate solitary pulmonary nodules with.
Hung GU; Shiau YC; Tsai SC; Ho YJ; Kao CH; Yen RF
Jpn J Clin Oncol; 2001 Feb; 31(2):51-4. PubMed ID: 11302341
[TBL] [Abstract][Full Text] [Related]
8. Indeterminate lung nodules in cancer patients: pretest probability of malignancy and the role of 18F-FDG PET/CT.
Evangelista L; Panunzio A; Polverosi R; Pomerri F; Rubello D
AJR Am J Roentgenol; 2014 Mar; 202(3):507-14. PubMed ID: 24555586
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
11. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
12. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
Dewan NA; Reeb SD; Gupta NC; Gobar LS; Scott WJ
Chest; 1995 Aug; 108(2):441-6. PubMed ID: 7634881
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary nodules: differential diagnosis using 18F-fluorodeoxyglucose single-photon emission computed tomography.
Worsley DF; Celler A; Adam MJ; Kwong JS; Müller NL; Coupland DB; Champion P; Finley RJ; Evans KG; Lyster DM
AJR Am J Roentgenol; 1997 Mar; 168(3):771-4. PubMed ID: 9057532
[TBL] [Abstract][Full Text] [Related]
14. Solitary pulmonary nodule evaluation in regions endemic for infectious diseases: Do regional variations impact the effectiveness of fluorodeoxyglucose positron emission tomography/computed tomography.
Purandare NC; Pramesh CS; Agarwal JP; Agrawal A; Shah S; Prabhash K; Karimundackal G; Jiwnani S; Tandon S; Rangarajan V
Indian J Cancer; 2017; 54(1):271-275. PubMed ID: 29199704
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules.
Maiga AW; Deppen SA; Mercaldo SF; Blume JD; Montgomery C; Vaszar LT; Williamson C; Isbell JM; Rickman OB; Pinkerman R; Lambright ES; Nesbitt JC; Grogan EL
JAMA Surg; 2018 Apr; 153(4):329-334. PubMed ID: 29117314
[TBL] [Abstract][Full Text] [Related]
16.
Taralli S; Scolozzi V; Foti M; Ricciardi S; Forcione AR; Cardillo G; Calcagni ML
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):429-436. PubMed ID: 30535767
[TBL] [Abstract][Full Text] [Related]
17. PET in lung cancer.
Coleman RE
J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
[TBL] [Abstract][Full Text] [Related]
18. 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm.
Divisi D; Di Tommaso S; Di Leonardo G; Brianzoni E; De Vico A; Crisci R
Thorac Cardiovasc Surg; 2010 Oct; 58(7):422-6. PubMed ID: 20922626
[TBL] [Abstract][Full Text] [Related]
19. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
[TBL] [Abstract][Full Text] [Related]
20. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography.
Hagberg RC; Segall GM; Stark P; Burdon TA; Pompili MF
Eur J Cardiothorac Surg; 1997 Jul; 12(1):92-7. PubMed ID: 9262087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
